Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 130

Sort by

Sort Order Select

Journal Articles

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

Johann K. Hitzler, Todd A. Alonzo, Robert Gerbing, Jim Wang, Amy Beckman, Betsy Hirsch, Susana C. Raimondi, Karen M Chisholm, Shelton A. Viola, Anupam Verma, Lisa Eidenschink Brodersen, Michael R. Loken, Jeffrey W. Taub, Alan S Gamis, E. Anders Kolb, Todd M Cooper, Jason N. Berman

Blood (2024) 144 (Supplement 1): 2949.

https://doi.org/10.1182/blood-2024-202621

Published: 2024

Journal Articles

Genome-Wide Association Study Identifies Variants Associated with Clinical Outcomes in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia

Richard J Marrero, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Susana C. Raimondi, Ching-Hon Pui, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds, Jatinder K. Lamba

Blood (2022) 140 (Supplement 1): 6295–6296.

https://doi.org/10.1182/blood-2022-159534

Published: 2022

Journal Articles

Personalization of Induction Therapy for Pediatric AML to Ara-C+Dauno+ Etoposide (ADE) or Clofarabine+Ara-C According to a Polygenic Ara-C SNP Score- ACS10

Jatinder K. Lamba, Richard J Marrero, Abdelrahman H Elsayed, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Susana C. Raimondi, Ching-Hon Pui, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds

Blood (2022) 140 (Supplement 1): 1039–1040.

https://doi.org/10.1182/blood-2022-159657

Published: 2022

Journal Articles

Clofarabine-Based Chemotherapy for KMT2A r Infantile Acute Lymphoblastic Leukemia

Tanja Andrea Gruber, Deqing Pei, John Kim Choi, Cheng Cheng, Elaine Coustan-Smith, Dario Campana, Hope Swanson, Jennifer L Pauley, Hiroto Inaba, Monika Metzger, Jeffrey E. Rubnitz, Raul C Ribeiro, Susana C. Raimondi, William E. Evans, Mary V. Relling, Ching-Hon Pui, Sima Jeha

Blood (2021) 138 (Supplement 1): 3406.

https://doi.org/10.1182/blood-2021-148936

Published: 2021

Journal Articles

The Molecular Characteristics and Clinical Relevance of NUP98 -Other Translocations in Pediatric Acute Myeloid Leukemia

Eline J.M. Bertrums, Jenny L. Smith, MSc, MD, Rhonda E. Ries, MA, Todd A. Alonzo, PhD, Fabiana Ostronoff, MD, Gertjan J.L. Kaspers, Prof. MD PhD, Henrik Hasle, PhD, Christian M. Zwaan, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd M. Cooper, DO, Richard Aplenc, MD PhD, Alan S. Gamis, MD MPH, Edward A. Kolb, MD, Bianca F. Goemans, MD PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-137537

Published: 2020

Journal Articles

Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-137244

Published: 2020

Journal Articles

Genomic Analysis of Congenital Myeloid Sarcoma Identifies Significant Bone Marrow Involvement in the Absence of Morphologic Blasts

Jennifer Kamens, MD, Jinjun Dang, PhD, Sarah Aldridge, MSN, Jing Ma, PhD, Yuanyuan Wang, PhD, Gang Wu, PhD, Vasiliki Leventaki, MD, Susana C. Raimondi, PhD, Joy Nakitandwe, PhD, Alberto Pappo, MD, Tanja Gruber, MDPhD

Blood (2020) 136 (Supplement 1): 41.

https://doi.org/10.1182/blood-2020-142168

Published: 2020

Journal Articles

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

Rhonda E. Ries, MA, Amanda R. Leonti, MS, Timothy Junius Triche, Jr., PhD, Robert B. Gerbing, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Jenny L. Smith, MSc, MD, Todd M Cooper, DO, Jason E. Farrar, MD, Aniruddha J. Deshpande, E. Anders Kolb, MD, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 461.

https://doi.org/10.1182/blood-2019-125943

Published: 2019

Journal Articles

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

Jessica A. Pollard, MD, Todd A. Alonzo, PhD, Patrick A. Brown, MD, Robert B. Gerbing, Elizabeth Fox, MD, John Kim Choi, MD, Brian T. Fisher, DO, MSCE, Betsy A Hirsch, PhD, Samir Kahwash, MD, John E. Levine, MDMS, Michael R. Loken, PhD, Susana C. Raimondi, PhD, Katherine Tarlock, MD, Andrew C. Wood, MBCHB, Lillian Sung, MD PhD, Anders E. Kolb, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Richard Aplenc, MD PhD

Blood (2019) 134 (Supplement_1): 292.

https://doi.org/10.1182/blood-2019-129557

Published: 2019

Journal Articles

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Johann K. Hitzler, MD, Jason Berman, MD, Robert B. Gerbing, Amy Beckman, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd E Druley, MD PhD, Michael R. Loken, PhD, Lisa Eidenschink Brodersen, PhD, Karen Chisholm, Shelton A. Viola, MD, Jeffrey W. Taub, MD, Alan S Gamis, MD MPH, Todd A. Alonzo, PhD, E. Anders Kolb, MD

Blood (2019) 134 (Supplement_1): 118.

https://doi.org/10.1182/blood-2019-126723

Published: 2019

Journal Articles

A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome

Abdelrahman H. Elsayed, MSc, Huiyun Wu, PhD, Xueyuan Cao, PhD, Susana C. Raimondi, PhD, James R. Downing, MD, Raul Ribeiro, MD, Tanja A. Gruber, MD PhD, Rhonda E. Ries, MA, Soheil Meshinchi, MD PhD, Jeffrey Rubnitz, MD PhD, Stanley Pounds, PhD, Jatinder K Lamba, M.Sc., PhD

Blood (2019) 134 (Supplement_1): 1429.

https://doi.org/10.1182/blood-2019-128787

Published: 2019

Journal Articles

Hypodiploidy in Childhood Acute Myeloid Leukemia: A Retrospective Cohort Study within the International Berlin-Frankfurt-Münster Study Group

Blood (2018) 132 (Supplement 1): 1466.

https://doi.org/10.1182/blood-2018-99-109988

Published: 2018

Journal Articles

Pediatric LSC3 (pLSC3) Score Derived from DNMT3B-CD34-GPR56 As a Prognostic Tool to Predict AML Patient Outcome: Results from Two Independent Pediatric AML Cohorts

Abdelrahman H Elsayed, MSc, Huiyun Wu, PhD, Xueyuan Cao, PhD, Susana C. Raimondi, PhD, James R. Downing, MD, Raul Ribeiro, MD, Tanja A. Gruber, MD PhD, Jeffrey Rubnitz, MD PhD, Stanley Pounds, PhD, Jatinder K Lamba, PhD

Blood (2018) 132 (Supplement 1): 290.

https://doi.org/10.1182/blood-2018-99-116462

Published: 2018

Journal Articles

CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial

Jatinder Lamba, PhD, Lata Chauhan, PhD, Miyoung Shin, PhD, Michael R. Loken, PhD, Jessica A. Pollard, MD, Jim Wang, Richard Aplenc, MD, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Irwin D. Bernstein, MD, Alan S Gamis, MD MPH, Todd A Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 3826.

https://doi.org/10.1182/blood.V130.Suppl_1.3826.3826

Published: 2017

Journal Articles

Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Todd M Cooper, DO, Rhonda E. Ries, MA, Todd A Alonzo, PhD, Robert B Gerbing, Michael R. Loken, PhD, Lisa E. Brodersen, PhD, Susana C. Raimondi, PhD, Betsy A Hirsch, PhD, Richard Aplenc, MD, Alan S Gamis, MD MPH, Edward A Kolb, MD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 407.

https://doi.org/10.1182/blood.V130.Suppl_1.407.407

Published: 2017

Journal Articles

Functional Properties of Exon 17 KIT Mutations in Pediatric CBF AML Predict for Inferior Outcome and Enhanced Response to Tyrosine Kinase Inhibition: A Report from the Children's Oncology Group

Katherine Tarlock, MD, Todd A Alonzo, PhD, Robert B Gerbing, Yi-Cheng Wang, Rhonda E. Ries, MA, Tiffany Hylkema, BS, Jason Joaquin, Susana C. Raimondi, PhD, Betsy A Hirsch, PhD, Edward A Kolb, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Jessica A. Pollard, MD

Blood (2017) 130 (Supplement 1): 25.

https://doi.org/10.1182/blood.V130.Suppl_1.25.25

Published: 2017

Journal Articles

Distinct Outcome Based on Fusion Transcript in t(16;21) Rearranged Pediatric AML, a Collaborative Retrospective Analysis By the I-BFM SG

Blood (2017) 130 (Supplement 1): 184.

https://doi.org/10.1182/blood.V130.Suppl_1.184.184

Published: 2017

Journal Articles

Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial

Lata Chauhan, PhD, Todd A Alonzo, PhD, Jim Wang, Michael R. Loken, PhD, Jessica A. Pollard, MD, Richard Aplenc, MD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Betsy A Hirsch, PhD, Irwin D. Bernstein, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Jatinder Lamba, PhD

Blood (2017) 130 (Supplement 1): 2526.

https://doi.org/10.1182/blood.V130.Suppl_1.2526.2526

Published: 2017

Journal Articles

Characteristics and Outcomes of Pediatric Patients with t(16;16)-AML: Results of a Case Series By the International BFM Study Group

Kim Klein, MD MSc, Valerie de Haas, MD PhD, Jonas Abrahamsson, MD PhD, Todd A Alonzo, PhD, Brenda Gibson, MD PhD, Christine J Harrison, PhD FRCPath, Henrik Hasle, MD PhD, Betsy A Hirsch, PhD, Guy Leverger, MD PhD, Franco Locatelli, MD PhD, Susana C. Raimondi, PhD, Jeffrey E Rubnitz, MD PhD, Dirk Reinhardt, MD PhD, Daisuke Tomizawa, MD PhD, Gertjan J.L. Kaspers, MD PhD

Blood (2017) 130 (Supplement 1): 2671.

https://doi.org/10.1182/blood.V130.Suppl_1.2671.2671

Published: 2017

Journal Articles

Gemtuzumab ozogamicin in infants with AML: results from the Children’s Oncology Group trials AAML03P1 and AAML0531

Erin M. Guest, Richard Aplenc, Lillian Sung, Susana C. Raimondi, Betsy A. Hirsch, Todd A. Alonzo, Robert B. Gerbing, Yi-Cheng Jim Wang, Samir B. Kahwash, Amy Heerema-McKenney, Soheil Meshinchi, Alan S. Gamis

Blood (2017) 130 (7): 943–945.

https://doi.org/10.1182/blood-2017-01-762336

Published: 2017

Includes: Supplemental data

NARROW

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

Genome-Wide Association Study Identifies Variants Associated with Clinical Outcomes in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia

Personalization of Induction Therapy for Pediatric AML to Ara-C+Dauno+ Etoposide (ADE) or Clofarabine+Ara-C According to a Polygenic Ara-C SNP Score- ACS10

Clofarabine-Based Chemotherapy for KMT2A r Infantile Acute Lymphoblastic Leukemia

The Molecular Characteristics and Clinical Relevance of NUP98 -Other Translocations in Pediatric Acute Myeloid Leukemia

Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts

Genomic Analysis of Congenital Myeloid Sarcoma Identifies Significant Bone Marrow Involvement in the Absence of Morphologic Blasts

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome

Hypodiploidy in Childhood Acute Myeloid Leukemia: A Retrospective Cohort Study within the International Berlin-Frankfurt-Münster Study Group

Pediatric LSC3 (pLSC3) Score Derived from DNMT3B-CD34-GPR56 As a Prognostic Tool to Predict AML Patient Outcome: Results from Two Independent Pediatric AML Cohorts

CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial

Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Functional Properties of Exon 17 KIT Mutations in Pediatric CBF AML Predict for Inferior Outcome and Enhanced Response to Tyrosine Kinase Inhibition: A Report from the Children's Oncology Group

Distinct Outcome Based on Fusion Transcript in t(16;21) Rearranged Pediatric AML, a Collaborative Retrospective Analysis By the I-BFM SG

Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial

Characteristics and Outcomes of Pediatric Patients with t(16;16)-AML: Results of a Case Series By the International BFM Study Group

Gemtuzumab ozogamicin in infants with AML: results from the Children’s Oncology Group trials AAML03P1 and AAML0531

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only